2025
NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression.
Giridharan T, Suzuki S, Khan A, Liu Q, Attwood K, Stokolosa A, Mahan S, Witkiewicz A, Joseph J, Moysich K, Langermann S, Lovewell R, Flies D, Myint H, Odunsi K, Emmons T, Yaffe M, Zsiros E, Dey P, McGray A, Segal B. NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. The Journal Of Immunology 2025 PMID: 40560129, DOI: 10.1093/jimmun/vkaf121.Peer-Reviewed Original ResearchOvarian cancerLAIR-2Immune cellsOverall survivalTumor cellsAssociated with better OSAssociated with worse overall survivalHigh-grade serous ovarian cancerNon-small cell lung cancerSingle-center retrospective analysisTumor-infiltrating immune cellsT-cell suppressor functionLAIR-1Stromal immune cellsT-cell non-responsivenessEpithelial ovarian cancerT cell suppressionSerous ovarian cancerCell lung cancerImmune cell infiltrationT cell proliferationT cell membraneOptimal debulkingMalignant effusionsAdvanced OCExposures to drinking water contaminants in community water systems and risk of ovarian cancer in the California Teachers Study cohort.
Spaur M, Hurwitz L, Medgyesi D, Keil A, Freeman L, Fisher J, Madrigal J, Ammons S, Spielfogel E, Bangia K, Albert P, Sanchez T, Lacey J, Jones R, Ward M. Exposures to drinking water contaminants in community water systems and risk of ovarian cancer in the California Teachers Study cohort. Environmental Health Perspectives 2025 PMID: 40471647, DOI: 10.1289/ehp16582.Peer-Reviewed Original ResearchHigh-grade serous histotypeOvarian cancer riskSerous histotypeOvarian cancerDrinking water contaminationCommunity water systemsWater contaminationCancer riskRisk of ovarian cancerCalifornia Teachers Study cohortEpithelial ovarian cancerOral contraceptive useCox proportional hazards regressionBody mass indexCalifornia Teachers StudyUranium concentrationProportional hazards regressionBilateral oophorectomyMenopausal statusCancer-freeProspective cohortWater systemsDrinking water exposureStudy cohortFollow-up
2024
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma
McNamara B, Greenman M, Bellone S, Santin L, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecologic Oncology 2024, 189: 16-23. PMID: 38981151, DOI: 10.1016/j.ygyno.2024.07.002.Peer-Reviewed Original ResearchTargets trophoblast cell-surface antigen-2Epithelial ovarian cancerAntibody-dependent cellular cytotoxicityPreclinical activityAntibody drug conjugatesOvarian cancerCell linesTumor cellsTrophoblast cell surface antigen 2Cell line-derived xenograft modelFlow cytometryCompared to tumor cellsEpithelial ovarian cancer cell linesOvarian cancer cell linesTumor cells in vitroOvarian cancer patientsPeripheral-blood lymphocytesEOC cell linesTumor growth suppressionAnnexin V-positiveGynecologic cancer mortalityIn vivo antitumor activityCells in vitroPrimary cell linesUnmet medical needPredictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients
C. M, Lavi E, Altwerger G, Lin Z, Ratner E. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLOS ONE 2024, 19: e0305273. PMID: 38976671, PMCID: PMC11230535, DOI: 10.1371/journal.pone.0305273.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerEpithelial ovarian cancer patientsEpithelial ovarian cancer casesGene mutation signaturesPlatinum-based chemotherapyThe Cancer Genome AtlasResponse to treatmentOverall survivalGene mutationsMutational signaturesHomologous recombinationSurvival outcomesIncreased sensitivity to platinum-based chemotherapySensitivity to platinum-based chemotherapyAssociated with increased chemoresistanceResistance to platinum-based chemotherapySurvival timeSurvival rateFavorable response to treatmentPlatinum-induced DNA damageKaplan-Meier survival analysisPrediction of survival outcomesOvarian cancer patientsOverall survival ratePrediction of treatment outcomeRacial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium
Meagher N, White K, Wilkens L, Bandera E, Berchuck A, Carney M, Cramer D, Cushing-Haugen K, Jordan S, Kaufmann S, Le N, Pike M, Riggan M, Qin B, Rothstein J, Titus L, Winham S, Anton-Culver H, Doherty J, Goode E, Pearce C, Risch H, Webb P, Cook L, Goodman M, Harris H, Le Marchand L, McGuire V, Pharoah P, Sarink D, Schildkraut J, Sieh W, Terry K, Thompson P, Whittemore A, Wu A, Peres L, Merritt M. Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium. American Journal Of Epidemiology 2024, 193: 1242-1252. PMID: 38775277, PMCID: PMC11369223, DOI: 10.1093/aje/kwae076.Peer-Reviewed Original ResearchConceptsOvarian Cancer Association ConsortiumEpithelial ovarian cancer riskNative Hawaiian/Pacific IslanderEpithelial ovarian cancerInverse associationHawaiian/Pacific IslanderRisk associationOdds ratioOvarian cancer riskRisk factor associationsTubal ligationLogistic regression modelsOral contraceptive (OCIslander womenCancer riskFactor associationsWhite participantsPrevention strategiesAsian womenOC useEthnic differencesRisk factorsGynecologic cancerRegression modelsOvarian cancerIntegrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions
Dareng E, Coetzee S, Tyrer J, Peng P, Rosenow W, Chen S, Davis B, Dezem F, Seo J, Nameki R, Reyes A, Aben K, Anton-Culver H, Antonenkova N, Aravantinos G, Bandera E, Freeman L, Beckmann M, Beeghly-Fadiel A, Benitez J, Bernardini M, Bjorge L, Black A, Bogdanova N, Bolton K, Brenton J, Budzilowska A, Butzow R, Cai H, Campbell I, Cannioto R, Chang-Claude J, Chanock S, Chen K, Chenevix-Trench G, Group A, Chiew Y, Cook L, DeFazio A, Dennis J, Doherty J, Dörk T, du Bois A, Dürst M, Eccles D, Ene G, Fasching P, Flanagan J, Fortner R, Fostira F, Gentry-Maharaj A, Giles G, Goodman M, Gronwald J, Haiman C, Håkansson N, Heitz F, Hildebrandt M, Høgdall E, Høgdall C, Huang R, Jensen A, Jones M, Kang D, Karlan B, Karnezis A, Kelemen L, Kennedy C, Khusnutdinova E, Kiemeney L, Kjaer S, Kupryjanczyk J, Labrie M, Lambrechts D, Larson M, Le N, Lester J, Li L, Lubiński J, Lush M, Marks J, Matsuo K, May T, McLaughlin J, McNeish I, Menon U, Missmer S, Modugno F, Moffitt M, Monteiro A, Moysich K, Narod S, Nguyen-Dumont T, Odunsi K, Olsson H, Onland-Moret N, Park S, Pejovic T, Permuth J, Piskorz A, Prokofyeva D, Riggan M, Risch H, Rodríguez-Antona C, Rossing M, Sandler D, Setiawan V, Shan K, Song H, Southey M, Steed H, Sutphen R, Swerdlow A, Teo S, Terry K, Thompson P, Thomsen L, Titus L, Trabert B, Travis R, Tworoger S, Valen E, Van Nieuwenhuysen E, Edwards D, Vierkant R, Webb P, Group O, Weinberg C, Weise R, Wentzensen N, White E, Winham S, Wolk A, Woo Y, Wu A, Yan L, Yannoukakos D, Zeinomar N, Zheng W, Ziogas A, Berchuck A, Goode E, Huntsman D, Pearce C, Ramus S, Sellers T, Consortium T, Freedman M, Lawrenson K, Schildkraut J, Hazelett D, Plummer J, Kar S, Jones M, Pharoah P, Gayther S. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions. American Journal Of Human Genetics 2024, 111: 1061-1083. PMID: 38723632, PMCID: PMC11179261, DOI: 10.1016/j.ajhg.2024.04.011.Peer-Reviewed Original ResearchTranscriptome-wide association studyRisk lociAssociation studiesTranscription factor ChIP-seqSusceptibility genesGenome-wide association analysisGenome-wide association studiesCausal risk variantsControls of European originTranscriptome-wide associationEpithelial ovarian cancerVariant Effect PredictorIntegrative multi-omics analysisMulti-omics analysisChIP-seqChromatin marksGenomic regionsFine-mappingSusceptibility lociInteractome analysisAssociation analysisEpithelial ovarian cancer histotypesRisk variantsTissue-specificLociAssociation between diet quality and ovarian cancer risk and survival
Cao A, Esserman D, Cartmel B, Irwin M, Ferrucci L. Association between diet quality and ovarian cancer risk and survival. Journal Of The National Cancer Institute 2024, 116: 1095-1104. PMID: 38400738, PMCID: PMC11223874, DOI: 10.1093/jnci/djae040.Peer-Reviewed Original ResearchOvarian cancer riskAll-Cause MortalityAssociated with lower all-cause mortalityDiet qualityCancer riskOvarian cancer diagnosisAssociated with ovarian cancer riskPre-DiagnosisProspective NIH-AARP DietHealthy Eating Index-2015Cancer diagnosisNIH-AARP DietStop Hypertension scoreCancer registry dataEpithelial ovarian cancerMediterranean diet scoreFood frequency questionnaireCox proportional hazards regressionOvarian cancerProportional hazards regressionHEI-2015Health StudyHypertension scoreDiet scoreFrequency questionnaire
2023
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib
Roberts C, Rojas-Alexandre M, Hanna R, Lin Z, Ratner E. Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib. Cancers 2023, 15: 3919. PMID: 37568736, PMCID: PMC10417836, DOI: 10.3390/cancers15153919.Peer-Reviewed Original ResearchEpithelial ovarian cancerRepair gene expressionPARP inhibitorsHomologous recombinationGene expressionDNA repair gene expressionCancer cellsLethal gynecologic malignancyDrug-resistant recurrenceDownregulation of genesOvarian cancer cellsGrowth factor betaWild-type cancer cellsDose-dependent mannerDNA repair genesGynecologic malignanciesMesenchymal tumorsOvarian tumorsEpithelial cell lineOvarian cancerMetastatic spreadClinical utilityEOC cellsFunctions of EMTFactor betaHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Original ResearchConceptsHyperthermic intraperitoneal chemotherapyIntraperitoneal chemotherapyOvarian cancerStage III epithelial ovarian cancerUse of HIPECEpithelial ovarian cancerHigh-quality evidenceOvarian cancer treatmentHIPEC useInterval cytoreductionCytoreductive surgeryNeoadjuvant chemotherapyPerioperative careHIPEC protocolsHIPEC techniqueTreatment modalitiesPatient outcomesSingle administrationTumor disseminationChemotherapyCancerCancer treatmentOptimal candidatesMain siteLife dataSafety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Santin A, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland L, Monk B, Coleman R, Herzog T, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter A, Childs B, Elbi C, Bulat I. Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. International Journal Of Gynecological Cancer 2023, 33: 1-9. PMID: 36564099, PMCID: PMC10086500, DOI: 10.1136/ijgc-2022-003927.Peer-Reviewed Original ResearchConceptsPlatinum-resistant ovarian cancerProgression-free survivalMedian progression-free survivalAnetumab ravtansineObjective response rateOvarian cancerLiposomal doxorubicinMedian durationAdverse eventsDose escalationMesothelin expressionCommon treatment-emergent adverse eventsPlatinum-resistant epithelial ovarian cancerResponse rateAnti-mesothelin monoclonal antibodyTreatment-emergent adverse eventsHigh mesothelin expressionPegylated-liposomal doxorubicinPhase Ib studyPhase III studyDose-limiting toxicityPromising clinical activityEpithelial ovarian cancerAnti-tumor activityCentral immunohistochemistryLifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Fu Z, Brooks M, Irvin S, Jordan S, Aben K, Anton-Culver H, Bandera E, Beckmann M, Berchuck A, Brooks-Wilson A, Chang-Claude J, Cook L, Cramer D, Cushing-Haugen K, Doherty J, Ekici A, Fasching P, Fortner R, Gayther S, Gentry-Maharaj A, Giles G, Goode E, Goodman M, Group A, Harris H, Hein A, Kaaks R, Kiemeney L, Köbel M, Kotsopoulos J, Kotsopoulos J, Le N, Lee A, Matsuo K, McGuire V, McLaughlin J, Menon U, Milne R, Moysich K, Pearce C, Pike M, Qin B, Ramus S, Riggan M, Rothstein J, Schildkraut J, Sieh W, Sutphen R, Terry K, Thompson P, Titus L, van Altena A, White E, Whittemore A, Wu A, Zheng W, Ziogas A, Taylor S, Tang L, Songer T, Wentzensen N, Webb P, Risch H, Modugno F. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. Journal Of The National Cancer Institute 2023, 115: 539-551. PMID: 36688720, PMCID: PMC10165492, DOI: 10.1093/jnci/djad011.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOral contraceptive useClear cell histotypeOvulatory yearsOvulation suppressionOdds ratioOvarian cancerContraceptive useNonmucinous epithelial ovarian cancerConfidence intervalsConsistent protective effectCase patientsMucinous tumorsPooled analysisProtective effectEOC riskControl participantsHistotypeCancerOvulationAssociationRegression modelsRiskYearsBeta coefficientsChapter 3 Ovarian carcinosarcoma
Tymon-Rosario J, Chui M, Santin A. Chapter 3 Ovarian carcinosarcoma. 2023, 41-54. DOI: 10.1016/b978-0-323-82938-0.00003-3.Peer-Reviewed Original ResearchHigh-grade serous ovarian carcinomaSurvival of womenEpithelial ovarian cancerSerous ovarian carcinomaEpithelial-mesenchymal transitionCarcinosarcoma patientsGynecologic tractHistologic subtypeOvarian carcinosarcomaAggressive diseaseAggressive malignancyCarcinoma componentOvarian tumorsClinical managementOvarian carcinomaClinical trialsOvarian cancerSarcomatous elementsAggressive natureCarcinosarcomaTumorsDiseaseSurvivalMolecular studiesPatients
2022
EP015/#546 In vitro and in vivo efficacy of trastuzumab deruxtecan (T-DXd) in epithelial ovarian cancer with HER2/NEU overexpression
Mutlu L, Manavella D, Bellone S, Santin A. EP015/#546 In vitro and in vivo efficacy of trastuzumab deruxtecan (T-DXd) in epithelial ovarian cancer with HER2/NEU overexpression. International Journal Of Gynecological Cancer 2022, 32: a54. DOI: 10.1136/ijgc-2022-igcs.106.Peer-Reviewed Original ResearchHER2/neu overexpressionEpithelial ovarian cancerTrastuzumab deruxtecanNeu overexpressionOvarian cancerVivo efficacy50 The role of DNA methyltransferase inhibitors (DNMTi) in the treatment of patients with recurrent epithelial ovarian cancer: a systematic review and meta-analysis
Shafa A, Kailasam A, Prokop L, Hou X, Weroha S. 50 The role of DNA methyltransferase inhibitors (DNMTi) in the treatment of patients with recurrent epithelial ovarian cancer: a systematic review and meta-analysis. Gynecologic Oncology Reports 2022, 44: s24. DOI: 10.1016/s2352-5789(22)00262-4.Peer-Reviewed Original ResearchRecurrent epithelial ovarian cancerEpithelial ovarian cancerDNA methyltransferase inhibitorClinical benefit ratioProgression free survivalOvarian cancerRandom-effects modelFree survivalOverall survivalClinical benefitMeta-analysisTherapeutic optionsAdverse eventsTreatment of recurrent epithelial ovarian cancerClinical trialsMethyltransferase inhibitorSystematic reviewResponse rateRecurrent ovarian cancerPrevalence of adverse eventsTreatment of patientsHypomethylating agentsNCI-CTCAEEfficacy outcomesPoor prognosisHigh pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival
Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharaoh P, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL. High pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival. Cancer Epidemiology Biomarkers & Prevention 2022, 31: cebp.epi-21-0977-a.2021. PMID: 34789471, PMCID: PMC9281656, DOI: 10.1158/1055-9965.epi-21-0977.Peer-Reviewed Original ResearchConceptsOvarian cancer survivalCox proportional hazards modelProportional hazards modelCancer survivalOvarian cancerRisk scoreHazards modelNonsteroidal anti-inflammatory drug useAnti-inflammatory drug useMenopausal hormone therapy useEnvironmental tobacco smoke exposureInvasive epithelial ovarian cancerHormone therapy usePelvic inflammatory diseaseInflammation-related factorsPolycystic ovarian syndromeTobacco smoke exposureBody mass indexRisk of deathEpithelial ovarian cancerOvarian Cancer Association ConsortiumOvarian cancer diagnosisHigh death rateAspirin useOvarian syndrome
2021
Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment
Tymon-Rosario J, Adjei NN, Roque DM, Santin AD. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment. Cancers 2021, 13: 6239. PMID: 34944858, PMCID: PMC8699494, DOI: 10.3390/cancers13246239.Peer-Reviewed Original ResearchEpithelial ovarian cancerOvarian cancerClinical dataEpithelial ovarian cancer treatmentTaxane-treated patientsUse of ixabepiloneRefractory ovarian cancerOngoing clinical trialsStandard of careOvarian cancer treatmentClinical trialsRecurrent treatmentTaxane resistanceCurrent standard practiceChemotherapeutic agentsTherapeutic agentsCancerCancer treatmentPutative mechanismsMicrotubular functionTreatmentDrugs partTaxanesCell deathCurrent useA Benzenesulfonamide-based Mitochondrial Uncoupler Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Epithelial Ovarian Cancer
Bi F, Jiang Z, Park W, Hartwich TMP, Ge Z, Chong KY, Yang K, Morrison MJ, Kim D, Kim J, Zhang W, Kril LM, Watt DS, Liu C, Yang-Hartwich Y. A Benzenesulfonamide-based Mitochondrial Uncoupler Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Epithelial Ovarian Cancer. Molecular Cancer Therapeutics 2021, 20: molcanther.mct-21-0396-a.2021. PMID: 34625503, PMCID: PMC8643344, DOI: 10.1158/1535-7163.mct-21-0396.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerImmunogenic cell deathOvarian cancerTumor progressionAntitumor adaptive immune responsesDamage-associated molecular patternsCancer cellsMitochondrial uncouplerAdaptive immune responsesOvarian cancer modelCause of deathCurrent chemotherapeutic agentsNew therapeutic strategiesOvarian cancer cellsCancer cell proliferationCell deathEndoplasmic reticulum stressGynecologic malignanciesClinical outcomesEndoplasmic reticulum stress sensorNew anticancer therapiesPeritoneal fluidInduces Endoplasmic Reticulum StressImmune responseAbdominal cavityEndometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Khoja L, Weber RP, Group T, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology 2021, 164: 195-201. PMID: 34776242, PMCID: PMC9444325, DOI: 10.1016/j.ygyno.2021.10.088.Peer-Reviewed Original ResearchConceptsHistory of endometriosisOvarian cancer riskEPT useOvarian Cancer Association ConsortiumOvarian cancerInverse associationOdds ratioCancer riskCancer associationInvasive epithelial ovarian cancerHormone therapy useMenopausal hormone therapyEpithelial ovarian cancerCase-control studyConfidence intervalsSlight inverse associationWarrants further investigationHormone therapyTherapy usePooled analysisEndometriosisHysterectomyCancerTherapySelf-reported dataPrediagnosis and postdiagnosis leisure time physical activity and survival following diagnosis with ovarian cancer
Wang T, Townsend MK, Eliassen AH, Terry KL, Song M, Irwin ML, Tworoger SS. Prediagnosis and postdiagnosis leisure time physical activity and survival following diagnosis with ovarian cancer. International Journal Of Cancer 2021, 149: 1067-1075. PMID: 33963766, PMCID: PMC8282739, DOI: 10.1002/ijc.33676.Peer-Reviewed Original ResearchConceptsOvarian cancer-specific mortalityCancer-specific mortalityNurses' Health StudyPhysical activityHazard ratioOvarian cancerHealth StudyWeek 1MET-hours/weekLow-grade serous tumorsLeisure-time physical activityPostdiagnosis physical activityRisk of deathEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsTime physical activityOvarian cancer diagnosisBetter prognosisSerous tumorsCancer survivalInverse associationLarge cohortDiagnosisCancer diagnosisIn silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer
Lin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES. In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer. Scientific Reports 2021, 11: 8042. PMID: 33850183, PMCID: PMC8044145, DOI: 10.1038/s41598-021-87325-5.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerSmall molecule inhibitorsPARP inhibitor resistancePARP inhibitorsBRCA mutationsOvarian cancerEOC cellsPoly ADP-ribose polymerase inhibitorsMolecule inhibitorsInhibitor resistanceADP-ribose polymerase inhibitorsTumor-bearing miceNovel small molecule inhibitorPARP inhibitor olaparibDefective homologous recombination (HR) repairEOC xenograftsClinical efficacySurvival timePutative small molecule inhibitorsInhibitor olaparibPolymerase inhibitorsHR repairInhibitorsCancerHomologous recombination repair
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply